<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03217331</url>
  </required_header>
  <id_info>
    <org_study_id>CARD-LV01</org_study_id>
    <nct_id>NCT03217331</nct_id>
  </id_info>
  <brief_title>CRD-102 for Right Heart Failure in Patients With Left Ventricular Assist Devices</brief_title>
  <official_title>CRD-102 for Right Heart Failure in Patients With Left Ventricular Assist Devices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiora Pty. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiora Pty. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b/IIa, single centre, non-randomised open-label uncontrolled study to assess
      safety, effect and PK of oral CRD-102 in patients with RHF associated with the presence of an
      LVAD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted over a 40 day time period inclusive of screening and follow up
      time periods. Eligible subjects will receive oral CRD-102 for 14 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Subject incidence of adverse events</measure>
    <time_frame>40 days</time_frame>
    <description>Number of adverse events as a measure of safety and tolerability.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Exploratory: Pulmonary artery pressures (mmHg).</measure>
    <time_frame>40 days</time_frame>
    <description>Changes compared to baseline in Pulmonary artery pressures (mmHg)</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory: Left ventricular ejection fraction (%)</measure>
    <time_frame>40 days</time_frame>
    <description>Changes compared to baseline in left ventricular ejection fraction (%)</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory: Quality of life (KCCQ questionnaire)</measure>
    <time_frame>40 days</time_frame>
    <description>Changes compared to baseline in Quality of life (KCCQ questionnaire)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Right Heart Failure</condition>
  <condition>Left Ventricular Assist Device</condition>
  <arm_group>
    <arm_group_label>CRD-102 Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRD102 Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CRD-102</intervention_name>
    <description>14 mg CRD-102 capsules administered twice daily orally for 14 days.</description>
    <arm_group_label>CRD-102 Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients are enrolled only if they met the following criteria.

          1. Males and females aged 18-85 years inclusive

          2. Have received a LVAD (HeartWare HVAD, HeartMate II) at least 30 days prior to
             screening.

          3. Stable LVAD patients with evidence of ongoing right heart failure as evidenced by
             raised right atrial pressure indicated by JVP &gt;6cm OR measured right atrial pressure
             â‰¥12mmHg within the 3 months prior to or at Baseline OR dilated IVC on echocardiography
             PLUS all of the following;

               1. ongoing diuretic therapy;

               2. echocardiography in the 3 months prior to or at Baseline showing at least mild
                  impairment in overall RV systolic function by visual assessment together with a
                  TAPSE &lt; 14mm.

          4. Able to give written informed consent and agree to adhere to all protocol
             requirements.

          5. All patients will be required to have an implanted cardiaoverter defibrillator. (ICD)

        Exclusion Criteria:

          1. Hemodynamically unstable patients.

          2. Hypotension (MAP&lt;60 or systolic BP &lt;90 mmHg) at Screening or Baseline

          3. Hypertension (MAP&gt;95 or systolic BP &gt;130 mmHg) at Screening or Baseline

          4. Ventricular tachycardia or ventricular fibrillation in the past 30 days or poorly
             controlled atrial fibrillation (ventricular rate &gt;120 bpm)

          5. Concurrent participation in another investigational device study or prior
             participation in which a device was implanted and remains in place

          6. Receipt of any investigational research agent within 30 days or 5 half-lives
             (whichever is longer) prior to Baseline.

          7. Current treatment with intravenous inotropes or levosimendan, or treatment within the
             2 weeks prior to Screening

          8. Significant renal (eGFR&lt;25 ml/min/1.73 sq m) or hepatic (bilirubin &gt;3mg/dL) impairment
             or anemia (Hb &lt;90g/dL) at Screening or Baseline.

          9. Expected heart transplantation within the study period.

         10. Pregnancy

         11. History of allergic reaction to milrinone or any excipients in the study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Kaye, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiora Pty. Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bob Soh, MD</last_name>
    <phone>+61 3 9657 0700</phone>
    <email>bob.soh@cardiora.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melissa Byrne, PhD</last_name>
    <phone>+61 3 9657 0700</phone>
    <email>melissa.byrne@cardiora.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Rodgers</last_name>
      <phone>773-702-5388</phone>
      <email>drodgers3@medicine.bsd.uchicago.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2017</study_first_submitted>
  <study_first_submitted_qc>July 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2017</study_first_posted>
  <last_update_submitted>January 28, 2018</last_update_submitted>
  <last_update_submitted_qc>January 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

